Background: Direct-acting antivirals are highly effective for the treatment of hepatitis C virus (HCV) infection, regardless race/ethnicity. We aimed to evaluate demographic, virological and clinical data of HCV-infected migrants vs. natives consecutively enrolled in the PITER cohort. Methods: Migrants were defined by country of birth and nationality that was different from Italy. Mann-Whitney U test, Chi-squared test and multiple logistic regression were used. Results: Of 10,669 enrolled patients, 301 (2.8%) were migrants: median age 47 vs. 62 years, (p < 0.001), females 56.5% vs. 45.3%, (p < 0.001), HBsAg positivity 3.8% vs. 1.4%, (p < 0.05). Genotype 1b was prevalent in both groups, whereas genotype 4 was more prevalent in migrants (p < 0.05). Liver disease severity and sustained virologic response (SVR) were similar. A higher prevalence of comorbidities was reported for natives compared to migrants (p < 0.05). Liver disease progression cofactors (HBsAg, HIV coinfection, alcohol abuse, potential metabolic syndrome) were present in 39.1% and 47.1% (p > 0.05) of migrants and natives who eradicated HCV, respectively. Conclusion: Compared to natives, HCV-infected migrants in care have different demographics, HCV genotypes, viral coinfections and comorbidities and similar disease severity, SVR and cofactors for disease progression after HCV eradication. A periodic clinical assessment after HCV eradication in Italians and migrants with cofactors for disease progression is warranted.
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort / Quaranta, M. G.; Ferrigno, L.; Tata, X.; D'Angelo, F.; Massari, M.; Coppola, C.; Biliotti, E.; Giorgini, A.; Laccabue, D.; Ciancio, A.; Blanc, P. L.; Margotti, M.; Ieluzzi, D.; Brunetto, M. R.; Barbaro, F.; Russo, F. P.; Beretta, I.; Morsica, G.; Verucchi, G.; Saracino, A.; Galli, M.; Kondili, L. A.; Mazzaro, C.; Bertola, M.; Benedetti, A.; Schiada, L.; Cucco, M.; Giacometti, A.; Brescini, L.; Castelletti, S.; Fiorentini, A.; Angarano, G.; Milella, M.; Leo, A. D.; Rendina, M.; Salvatore D'ABRAMO, F.; Lillo, C.; Iannone, A.; Piazzolla, M.; Badia, L.; Piscaglia, F.; Benevento, F.; Serio, I.; Castelli, F.; Zaltron, S.; Spinetti, A.; Odolini, S.; Bruno, R.; Mondelli, M.; Chessa, L.; Loi, M.; Torti, C.; Costa, C.; Mazzitelli, M.; Pisani, V.; Scaglione, V.; Trecarichi, E. M.; Zignego, A. L.; Monti, M.; Madia, F.; Attala, L.; Pierotti, P.; Salomoni, E.; Mariabelli, E.; Santantonio, T. A.; Bruno, S. R.; Cela, E. M.; Bassetti, M.; Mazzarello, G.; Alessandrini, A. I.; Biagio, A. D.; Nicolini, L. A.; Raimondo, G.; Filomia, R.; Aghemo, A.; Meli, R.; Lazzarin, A.; Salpietro, S.; Fracanzani, A. L.; Fatta, E.; Lombardi, R.; Lampertico, P.; Borghi, M.; D'Ambrosio, R.; Degasperi, E.; Puoti, M.; Baiguera, C.; D'Amico, F.; Vinci, M.; Rumi, M. G.; Zuin, M.; Zermiani, P.; Andreone, P.; Caraceni, P.; Guarneri, V.; Villa, E.; Bernabucci, V.; Bristot, L.; Paradiso, M. L.; Migliorino, G.; Gambaro, A.; Lapadula, G.; Spolti, A.; Soria, A.; Invernizzi, P.; Ciaccio, A.; Luca, M.; Malinverno, F.; Ratti, L.; Amoruso, D. C.; Pisano, F.; Scarano, F.; Staiano, L.; Morisco, F.; Cossiga, V.; Gentile, I.; Buonomo, A. R.; Foggia, M.; Zappulo, E.; Federico, A.; Dallio, M.; Coppola, N.; Sagnelli, C.; Martini, S.; Monari, C.; Nardone, G.; Sgamato, C.; Chemello, L.; Cavalletto, L.; Sterrantino, D.; Zanetto, A.; Zanaga, P.; Brancaccio, G.; Craxi, A.; Petta, S.; Calvaruso, V.; Crapanzano, L.; Madonia, S.; Cannizzaro, M.; Bruno, E. M.; Licata, A.; Amodeo, S.; Capitano, A. R.; Ferrari, C.; Negri, E.; Orlandini, A.; Pesci, M.; Gulminetti, R.; Pagnucco, L.; Parruti, G.; Stefano, P. D.; Coco, B.; Corsini, R.; Garlassi, E.; Andreoni, M.; Teti, E.; Cerva, C.; Baiocchi, L.; Grassi, G.; Gasbarrini, A.; Pompili, M.; Siena, M. D.; Taliani, G.; Spaziante, M.; Persico, M.; Masarone, M.; Aglitti, A.; Calvanese, G.; Anselmo, M.; Leo, P. D.; Marturano, M.; Saracco, G. M.; SVEGLIATI BARONI, Gianluca. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 53:12(2021), pp. 1603-1609. [10.1016/j.dld.2021.03.020]
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort
Giacometti A.;Brescini L.;Castelletti S.;SVEGLIATI BARONI, Gianluca
2021-01-01
Abstract
Background: Direct-acting antivirals are highly effective for the treatment of hepatitis C virus (HCV) infection, regardless race/ethnicity. We aimed to evaluate demographic, virological and clinical data of HCV-infected migrants vs. natives consecutively enrolled in the PITER cohort. Methods: Migrants were defined by country of birth and nationality that was different from Italy. Mann-Whitney U test, Chi-squared test and multiple logistic regression were used. Results: Of 10,669 enrolled patients, 301 (2.8%) were migrants: median age 47 vs. 62 years, (p < 0.001), females 56.5% vs. 45.3%, (p < 0.001), HBsAg positivity 3.8% vs. 1.4%, (p < 0.05). Genotype 1b was prevalent in both groups, whereas genotype 4 was more prevalent in migrants (p < 0.05). Liver disease severity and sustained virologic response (SVR) were similar. A higher prevalence of comorbidities was reported for natives compared to migrants (p < 0.05). Liver disease progression cofactors (HBsAg, HIV coinfection, alcohol abuse, potential metabolic syndrome) were present in 39.1% and 47.1% (p > 0.05) of migrants and natives who eradicated HCV, respectively. Conclusion: Compared to natives, HCV-infected migrants in care have different demographics, HCV genotypes, viral coinfections and comorbidities and similar disease severity, SVR and cofactors for disease progression after HCV eradication. A periodic clinical assessment after HCV eradication in Italians and migrants with cofactors for disease progression is warranted.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
